Impact of platinum-based chemotherapy on the progression of atherosclerosis

References

• Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 1980;64:1159–60
   PubMedGoogle Scholar
• Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986;105:48–51
   PubMed Web of Science ®Google Scholar
• Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol 1987;137:1236–7
   PubMed Web of Science ®Google Scholar
• Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26:485–90
   PubMed Web of Science ®Google Scholar
• Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33:1111–17
   PubMed Web of Science ®Google Scholar
• van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001;32:454–60
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236–41
   PubMed Web of Science ®Google Scholar
• Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250: H1145–9
   PubMed Web of Science ®Google Scholar
• Sagach VF, Tkachenko MN. On the mechanism of the involvement of endothelium in reactive hyperemia. Experientia 1991;47: 828–30
   PubMedGoogle Scholar
• Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111–15
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Akishita M, Eto M, et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995;92:3431–5
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725–32
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718–25
   PubMed Web of Science ®Google Scholar
• Nord C, Fossa SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 2003;88:36–41
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
   PubMed Web of Science ®Google Scholar
• Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002;25: 359–64
   PubMed Web of Science ®Google Scholar
• Donald AE, Charakida M, Cole TJ, et al. Non-invasive assessment of endothelial function: which technique? J Am Coll Cardiol 2006;48:1846–50
   PubMed Web of Science ®Google Scholar
• Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 2003;44: 125–31
   PubMed Web of Science ®Google Scholar
• Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–23
   PubMed Web of Science ®Google Scholar
• van den Belt-Dusebout AW, Nuver J, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467–75
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008;112:1949–53
   PubMed Web of Science ®Google Scholar
• Sagstuen H, Aass N, Fossa SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005;23:4980–90
   PubMed Web of Science ®Google Scholar
• Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokoyama M. Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 1999;276:H1927–34
   PubMed Web of Science ®Google Scholar
• Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597–601
   PubMed Web of Science ®Google Scholar
• Toutouzas PC, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis. Eur Heart J 1998;19:1504–11
   PubMed Web of Science ®Google Scholar
• Kinlay S, Fang JC, Hikita H, et al. Plasma alpha-tocopherol and coronary endothelium-dependent vasodilator function. Circulation 1999;100:219–21
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Davies G, Toutouzas P. Vitamin C increases nitric oxide availability in coronary atherosclerosis. Ann Intern Med 1999;131:156–7
   PubMed Web of Science ®Google Scholar
• Kugiyama K, Motoyama T, Hirashima O, et al. Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 1998;32:103–9
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222–9
   PubMed Web of Science ®Google Scholar
• Maxwell SR. Antioxidant vitamin supplements: update of their potential benefits and possible risks. Drug Saf 1999;21:253–66
   PubMed Web of Science ®Google Scholar
• Spencer AP, Carson DS, Crouch MA. Vitamin E and coronary artery disease. Arch Intern Med 1999;159:1313–20
   PubMed Web of Science ®Google Scholar
• Evans RW, Shaten BJ, Day BW, Kuller LH. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am J Epidemiol 1998;147:180–6
   PubMed Web of Science ®Google Scholar
• Kardinaal AF, Kok FJ, Ringstad J, et al. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC Study. Lancet 1993;342:1379–84
   PubMed Web of Science ®Google Scholar
• Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334: 1156–62
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–9
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447–55
   PubMed Web of Science ®Google Scholar
• de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89–95
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23–33
   PubMed Web of Science ®Google Scholar
• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154–60
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37–46
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:842–57
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–92
   PubMed Web of Science ®Google Scholar
• Portilla D, Dai G, McClure T, et al. Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 2002;62:1208–18
   PubMed Web of Science ®Google Scholar
• Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000;278:F667–75
   PubMed Web of Science ®Google Scholar
• Schonefeld M, Noble S, Bertorello AM, Mandel LJ, Creer MH, Portilla D. Hypoxia-induced amphiphiles inhibit renal Na  ++  , K(++)-ATPase. Kidney Int 1996;49:1289–96
   PubMed Web of Science ®Google Scholar
• Li S, Wu P, Yarlagadda P, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004;286:F572–80
   PubMed Web of Science ®Google Scholar
• Li S, Basnakian A, Bhatt R, et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004;287:F990–8
   PubMed Web of Science ®Google Scholar
• Portilla D, Schnackenberg L, Beger RD. Metabolomics as an extension of proteomic analysis: study of acute kidney injury. Semin Nephrol 2007;27:609–20
   PubMed Web of Science ®Google Scholar
• Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002;2:10.
   PubMedGoogle Scholar
• Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219–26
   PubMed Web of Science ®Google Scholar
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–9
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739–48
   PubMed Web of Science ®Google Scholar
• Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009;302:298–305
   PubMed Web of Science ®Google Scholar
• Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189–91
   PubMed Web of Science ®Google Scholar
• Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175: 1195–200
   PubMed Web of Science ®Google Scholar
• Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ.Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97: 555–60
   PubMed Web of Science ®Google Scholar